Fingerprint
Dive into the research topics of 'Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
R. K. Murthy*, S. Loi, A. Okines, E. Paplomata, E. Hamilton, S. A. Hurvitz, N. U. Lin, V. Borges, V. Abramson, C. Anders, P. L. Bedard, M. Oliveira, E. Jakobsen, T. Bachelot, S. S. Shachar, V. Muller, S. Braga, F. P. Duhoux, R. Greil, D. Cameron
*Corresponding author for this work
- University of Texas MD Anderson Cancer Center
- Peter Maccallum Cancer Centre
- Royal Marsden NHS Foundation Trust
- Emory University
- Sarah Cannon Research Institute
- University of California at Los Angeles
- Dana-Farber Cancer Institute
- University of Colorado Anschutz Medical Campus
- Vanderbilt University
- Duke University
- Princess Margaret Hospital
- University Hospital Vall d'Hebron
- University of Southern Denmark
- Centre Léon Bérard
- Rambam Health Care Campus Israel
- University of Hamburg
- Hospital Cuf Descobertas R. Mario Botas
- Université catholique de Louvain
- Paracelsus Private Medical University
- Edinburgh Cancer Research Centre
- University of North Carolina at Chapel Hill
- University of Nebraska Medical Center
- British Columbia Cancer
- German Breast Group
- Stanford University
- Seattle Genetics, Inc.
Research output: Contribution to journal › Article › peer-review